Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Osimertinib for EGFR-mutated NSCLC after adjuvant TKI progression
NCT06530719Phase 2
Key facts
- Status
- Not yet recruiting
- Start
- Jul 2024
- Primary completion
- May 2026
- Sponsor
- GeneFerm Biotechnology
- Modality
- Small Molecules
- Drugs
- osimertinib
- Conditions
- non-small cell lung cancer (NSCLC)
01
Overview
Phase 2, open-label trial of osimertinib in non-small cell lung cancer (NSCLC), sponsored by GeneFerm Biotechnology. Primary endpoint: Objective Remission Rate at 3 years. Planned start Jul 2024; status: not yet recruiting.
02
Design
- Study design
- Non-randomizedOpen-labelSingle group
03
Who it enrols
Patients with stage IB-IIIB EGFR-mutated NSCLC who progressed >3 months after adjuvant EGFR-TKI therapy following radical surgery.
04
Endpoints
Primary
Objective Remission Rate
Beyond the preview
Go deeper on NCT06530719.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06530719.